AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Audio By Carbonatix

VANCOUVER, British Columbia--(BUSINESS WIRE)--Oct 7, 2025--

AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:

• Truist Securities BioPharma Symposium, November 6, 2025
• Stifel Healthcare Conference, November 11-13, 2025
• Jefferies Global Healthcare Conference, November 18-20, 2025
• Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025

Visit AbCellera's Investor Relations website for additional information.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology. For more information, please visit www.abcellera.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251007123988/en/

CONTACT: Inquiries

Media: Tiffany Chiu;[email protected], +1(236)521-6774

Partnering: Murray McCutcheon, Ph.D.;[email protected], +1(604)559-9005

Investor Relations: Peter Ahn;[email protected], +1(778)729-9116

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: ONCOLOGY HEALTH RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY

SOURCE: AbCellera Biologics Inc.

Copyright Business Wire 2025.

PUB: 10/07/2025 04:05 PM/DISC: 10/07/2025 04:04 PM

http://www.businesswire.com/news/home/20251007123988/en